SCHEMBL594604

SCHEMBL594604

Cc1c(I)cccc1C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.52
ALDH1A1 P00352 5/20 0.50
KDM4E B2RXH2 4/20 0.50
HPGD P15428 4/20 0.50
HSD17B10 Q99714 3/20 0.50
ALOX15 P16050 1/20 0.48
NPC1 O15118 4/20 0.47
RAB9A P51151 4/20 0.47
CASP3 P42574 1/20 0.47
SENP8 Q96LD8 1/20 0.47
SENP7 Q9BQF6 1/20 0.47
SENP6 Q9GZR1 1/20 0.47
MYC P01106 2/20 0.46
CYP3A4 P08684 3/20 0.44
CYP2C9 P11712 3/20 0.44
KMT2A Q03164 3/20 0.44
MEN1 O00255 2/20 0.44
LMNA P02545 2/20 0.44
CYP1A2 P05177 2/20 0.44
PTGS2 P35354 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29731918 1.00 TSHR (0.52) TSHRALDH1A1KDM4EHPGDHSD17B10
Hydrochloric Acid SCHEMBL15351685 0.98 TSHR (0.50) TSHRALDH1A1KDM4EHPGDHSD17B10
Hydrochloric Acid SCHEMBL11231918 0.98 TSHR (0.50) TSHRALDH1A1KDM4EHPGDHSD17B10
SCHEMBL756585 0.84 TSHR (0.61) TSHRALDH1A1KDM4EHPGDHSD17B10
Benzene SCHEMBL27265959 0.84 TSHR (0.61) TSHRALDH1A1KDM4EHPGDHSD17B10
SCHEMBL27703149 0.84 TSHR (0.61) TSHRALDH1A1KDM4EHPGDHSD17B10
SCHEMBL19834671 0.83 BRPF1 (0.42) TSHRALDH1A1KDM4EHPGDHSD17B10
SCHEMBL10768142 0.81 TSHR (0.59) TSHRALDH1A1KDM4EHPGDHSD17B10
SCHEMBL28188375 0.81 TSHR (0.59) TSHRALDH1A1KDM4EHPGDHSD17B10
SCHEMBL27479457 0.81 TSHR (0.59) TSHRALDH1A1KDM4EHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 304 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116836081-A Ether epoxy toughening agent and preparation method and application thereof 中国林业科学研究院林产化学工业研究所 2023-10-03 CN claimed
CN-112876403-B Preparation method of apremilast impurity 成都摩尔生物医药有限公司 2022-10-21 CN claimed
CN-112876403-A Preparation method of apremilast impurity 成都摩尔生物医药有限公司 2021-06-01 CN claimed
EP-3059220-B1 METHOD OF PREPARING AND RECOVERING 2-METHYL-5-IODOBENZOIC ACID ABA CHEMICALS CORP (CN) 2018-12-05 EP claimed
US-10099981-B2 Methods for meta-arylation of aromatic alcohols UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2018-10-16 US claimed
EP-3059220-A1 METHOD OF PREPARING AND RECOVERING 2-METHYL-5-IODOBENZOIC ACID ABA Chemicals Corporation (CN) 2016-08-24 EP claimed
CN-103539662-B Preparation and recovery method of 2-methyl-5-iodobenzoic acid ABA CHEMICALS CORP 2015-04-08 CN claimed
CN-103539662-A Preparation and recovery method of 2-methyl-5-iodobenzoic acid ABA CHEMICALS CORP 2014-01-29 CN claimed
EP-1601642-A4 BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX RHEOGENE INC (US) 2007-04-11 EP claimed
EP-1601642-A2 BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX RheoGene, Inc. (US) 2005-12-07 EP claimed
WO-2004078924-A2 BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX RHEOGENE, INC. (US) 2004-09-16 WO claimed
US-4328162-A Process for preparing 9,11-unsaturated steroidal compound from the corresponding saturated steroidal compound EASTMAN KODAK COMPANY (US) 1982-05-04 US claimed
US-12569564-B2 Spirocyclic MDM2 modulator and uses thereof NEWAVE PHARMACEUTICAL INC. (US) 2026-03-10 US disclosed
US-20260014260-A1 MDM2 DEGRADER NEWAVE PHARMACEUTICAL INC (US) 2026-01-15 US disclosed
WO-2025262295-A1 PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 DARK BLUE THERAPEUTICS LTD (GB) 2025-12-26 WO disclosed
EP-4667466-A1 PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 Dark Blue Therapeutics Ltd (GB) 2025-12-24 EP disclosed
EP-0623123-A1 BENZOPYRAN AND RELATED LTB4 ANTAGONISTS. PFIZER (US) 1994-11-09 EP disclosed
EP-0609625-A1 Inhibitors of HIV protease useful for the treatment of AIDS ELI LILLY AND COMPANY (US) 1994-08-10 EP disclosed
WO-1993015067-A1 BENZOPYRAN AND RELATED LTB4 ANTAGONISTS PFIZER INC. (US) 1993-08-05 WO disclosed
US-4328162-A Process for preparing 9,11-unsaturated steroidal compound from the corresponding saturated steroidal compound EASTMAN KODAK COMPANY (US) 1982-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260014260-A1 MDM2 DEGRADER MDM2, TP53, ADRM1 TSHR 861/4885ALDH1A1 1614/4885KDM4E 3644/4885
US-10099981-B2 Methods for meta-arylation of aromatic alcohols ADH1C, ADH1A, ADH5 TSHR 2218/4885ALDH1A1 11/4885KDM4E 3165/4885
US-12569564-B2 Spirocyclic MDM2 modulator and uses thereof MDM2, TP53, XIAP TSHR 1018/4885ALDH1A1 1320/4885KDM4E 3943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.